Neoplasia/BPH

	Clinical and pathological factors associated with recurrence after radical cystectomy for bladder cancer: A single-center retrospective study. Pak J Med Sci Nusrat NB, Imtiaz S, Aslam A, Rehman AU, Muhammad S, Zafar N, Ashfaq AM, Arshad H. PMID: 42257077 [PubMed]
	Association of long-term 5Î±-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study. Front Pharmacol Lee S, Lee J, Min K, Tae JH, Lee CU, Choi J, Kim JH, Lee YS, Nguyen TT, Choi SY. PMID: 42256393 [PubMed]
	Assessing the hepatic and renal parameters of breast cancer patient blood samples before and after chemotherapy. Toxicol Rep Heilat GB, Alwidyan T, Alrosan AZ, Rataan AO, Alrosan K, Ahmad RB, Al-Kammash KR. PMID: 42255660 [PubMed]
	Progression-free Survival Following Primary Staging with [(18)F]PSMA-1007-PET/ceCT Versus Na[(18)F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial. Eur Urol Open Sci Buch-Olsen KM, Hansen S, Vilstrup MH, Poulsen MH, Holdgaard PC, Zieger KEA, Asmussen JT, Holm J, Pedersen KT, Hess S, Madsen SS, Eiber M, Gerke O, Hildebrandt MG. PMID: 42255253 [PubMed]
	The role of lysophosphatidic acid metabolism in castration-resistant prostate cancer progression. Front Oncol Feng J, Liu J, He Y. PMID: 42255241 [PubMed]
	Efficacy and safety of neoadjuvant therapies for high-risk and locally advanced prostate cancer in older adults: a systematic review and network meta-analysis. Front Oncol Yuan W, Wang Y, Liu Q, Tian F, Guo M. PMID: 42255215 [PubMed]
	Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities. Front Oncol Guo J, Wu K, Ma Z, Guo S, Wang F, Lu L. PMID: 42255210 [PubMed]
	New biosensor for the early detection of tPSA in the serum of prostate cancer patients using a Tb-anthracene-9-carboxaldehyde complex embedded in a modified cellulose polymer thin film. RSC Adv Abo Gabal MT, El-Desouky MA, Hanna DH, Attia MS. PMID: 42255141 [PubMed]
	"When the Doctor Said Cancer, Everything Stopped": A Qualitative Study of the Lived Experiences of Men With Prostate Cancer in Kenya. J Patient Exp Njuguna DW, Muthiru AW, Riogi B, Abdihamid O, Waihenya C, Chege S, Kibaya R, Mweni S, Kinya I, Nyabuto L, Murithi J, Kuno I, Caballero A, Afzal U, Makokha F, Cobran E. PMID: 42254549 [PubMed]
	CRISPR decodes the RNA regulatory network in prostate cancer: A review from mechanisms to precision therapeutics. Noncoding RNA Res Zhu S, Ni G, Zhang P, Yang Y, He H, Jiang J, Li Z. PMID: 42253611 [PubMed]
	Diagnostic challenges in pathologic staging of renal cell carcinoma following systemic immunotherapy. Am J Clin Pathol Hansen CA, Rose TL, Wobker SE. PMID: 42252791 [PubMed - in process]
	Impact of Simulated Radiation Dose Reduction on Deep Learning-Based Renal Segmentation Performance: A Simulation Study Using the KiTS21 (2021 Kidney and Kidney Tumor Segmentation Challenge) Dataset. Int Neurourol J Kim JS, Eun SJ. PMID: 42252648 [PubMed]
	Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial. Eur J Nucl Med Mol Imaging Pan J, Wang B, Zhu B, Gan H, Hu X, Liu X, Li X, Wu J, Wang H, Zhang Q, Liu C, Song S, Ma X, Ye D, Zhu Y. PMID: 42252348 [PubMed - as supplied by publisher]
	Integrative multi-omics identifies a glycosylation-based prognostic framework and nominates ALG3 for targeted therapy in bladder cancer. Discov Oncol Feng W, He W. PMID: 42251607 [PubMed - as supplied by publisher]
	Multi-dimensional profiling of lactylation-related signatures for prognostic and therapeutic insights in bladder cancer. Cancer Cell Int Zhao H, Li K, Xu H, Liao J, Zhuo C, Wang Q, Liu X, Kang Z, Zhu B, Lai X, Zhu S, Zhang Y, Zeng J. PMID: 42251369 [PubMed - as supplied by publisher]
	Diagnostic value of PSA-based markers in prostate cancer: a retrospective analysis stratified by body mass index. BMC Urol Yang T, Zhang Q, Liu Z, Tian J, Hu X, Lv Z. PMID: 42251295 [PubMed - as supplied by publisher]
	Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer. Ann Oncol Parker CTA, Huang HC, Grist E, Mendes L, Yamashita R, Croucher D, Sachdeva A, Murphy L, Liu VYT, Vidal SS, Todorovic T, Lall S, Goncalves M, Thakali S, Wingate A, Zakka L, Wetterskog D, Nowakowska K, Amos CL, STAMPEDE Collaborators, Berney DM, Tran PT, Spratt DE, Sydes MR, Brown LC, Zhao SG, Nguyen P, Clarke NW, Sweeney CJ, Stewart EL, Parmar MKB, Esteva A, James ND, Attard G. PMID: 42250604 [PubMed - as supplied by publisher]
	Glycovariant-based diagnosis of bladder cancer using urinary mucin 1 and carcinoembryonic antigen. J Pharm Biomed Anal Syed P, Islam MK, Kekki H, Terävä J, Lamminmäki U, Boström PJ, Leivo J, Gidwani K. PMID: 42250336 [PubMed - as supplied by publisher]
	Identification and external validation of a prognostic signature based on bone morphogenetic protein-related mRNAs for kidney renal clear cell carcinoma. Discov Oncol Zhou Y, Hu Z, Xie L, Zhang S, Huang Q, Zhang N, Liu Y, Zhang W, Wang K. PMID: 42250062 [PubMed - as supplied by publisher]
	Microstructure imaging of prostate cancer by diffusion MRI. MAGMA Szczepankiewicz F, Panagiotaki E, Molendowska M, Sandeman K, Palombo M, Wu D. PMID: 42250048 [PubMed - as supplied by publisher]

Articles 1 - 20 / 188406

Page 1 of 9421



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy